Sygnis SA (WSE:SYG)
2.060
0.00 (0.00%)
At close: Feb 5, 2026
Sygnis Revenue
Sygnis had revenue of 2.29M PLN in the quarter ending September 30, 2025, with 6.60% growth. This brings the company's revenue in the last twelve months to 15.41M, down -8.19% year-over-year. In the year 2023, Sygnis had annual revenue of 20.03M, down -29.73%.
Revenue (ttm)
15.41M
Revenue Growth
-8.19%
P/S Ratio
3.67
Revenue / Employee
856.22K
Employees
13
Market Cap
56.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 20.03M | -8.48M | -29.73% |
| Dec 31, 2022 | 28.51M | 25.11M | 739.70% |
| Dec 31, 2021 | 3.39M | 600.08K | 21.47% |
| Dec 31, 2020 | 2.79M | 509.95K | 22.32% |
| Dec 31, 2019 | 2.28M | -236.14K | -9.37% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.34B |
| Diagnostyka | 2.30B |
| Synektik Spólka Akcyjna | 681.60M |
| Voxel | 568.83M |
| BioMaxima | 59.11M |
| Read-Gene | 15.19M |
| Urteste | 1.80M |
| Pharmena | 1.27M |